Company intelligence / Profile preview
China Resources Boya Bio-pharmaceutical Group
- Ownership
- Private
- Employees
- ~1938
- Development stage
- Other
Overview
China Resources Boya/ Jiangxi Boya markets a commercial portfolio of plasma-derived blood products (human albumin, IVIG, rabies immunoglobulin, hepatitis B immunoglobulin, fibrinogen, coagulation factors) and several chemical/biochemical drugs (e.g., metformin, pioglitazone, glimepiride, oxytocin, heparin sodium), with products approved and sold in China; the company has also been involved in regulatory investigation of deaths linked to one IVIG batch in the past.
- Therapeutic areas
- HematologyImmunologyWomen's HealthEndocrinologyCardiovascularInfectious Diseases
- Modalities
- BiologicProteinImmunoglobulinSmall molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on China Resources Boya Bio-pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Resources Boya Bio-pharmaceutical Group.